RecruitingNCT07172243
BE.Amycon Biobank & Data Registry UZ Leuven
BE.Amycon Biobank & Data Registry UZ Leuven: Human Body Material (HBM) Collection and Data Collection of Patients With Amyloidosis
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
505 participants
Start Date
Sep 24, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Provide consent and sign informed consent form
- Age 18 years or older
- Diagnosis of amyloidosis (suspected or confirmed, any subtypes)
- For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis)
Exclusion Criteria2
- Not willing to sign informed consent
- Not able to sign informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07172243
Related Trials
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT0656389598 locations
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
NCT058986462 locations
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT0708164618 locations
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
NCT014082251 location
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT061929796 locations